ClinicalTrials.Veeva

Menu
P

Psychiatric Medicine Associates, LLC | Skokie, IL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Aticaprant
Psilocybin
CYB003
Esketamine
NSI-189
Flibanserin
SPD489
JNJ-67953964
Armodafinil
JNJ-42847922

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 23 total trials
Status recently updated

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" (APPROACH)

The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in part...

Enrolling
Active, not recruiting
Major Depressive Disorder
Behavioral: Psychological Support
Drug: CYB003

Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in ba...

Enrolling
Treatment Resistant Depression
Device: Vagus Nerve Stimulation (VNS)

The purpose of this study is to evaluate how well each individual dose of esketamine (56 milligrams \[mg\] and 84 mg) works when compared with placeb...

Enrolling
Depressive Disorder, Treatment-Resistant
Drug: Placebo
Drug: Esketamine 84 mg

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Active, not recruiting
Treatment Resistant Depression
Drug: Psilocybin

This is a long- term extension of the double-blind trials APPROACH (CYB003-002) and EMBRACE (CYB003-003). Its aim is to examine the safety and long-t...

Invitation-only
Major Depressive Disorder
Drug: CYB003

Trial sponsors

Janssen (J&J Innovative Medicine) logo
C
LivaNova logo
Allergan logo
Allergan logo
C
C
C
E
Janssen (J&J Innovative Medicine) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems